Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Clinical Trials Grant

Article summary

Marker Therapeutics has received a $2.6 million grant from the U.S. Food and Drug Administration to support a Phase 1 clinical study of its MT-601 therapy for pancreatic cancer.